The benefit, safety, and duration of anticoagulant treatment in patients with cirrhosis and portal vein thrombosis is contentious, so researchers sought to determine the impact the therapy has on survival...
Because irritable bowel syndrome is thought to be due to a disorder of brain–gut function, Dr Brian Lacy from Mayo Clinic and colleagues evaluated whether drugs acting centrally are effective in treating...
The American Gastroenterological Association has published new recommendations on which therapies are best for the management of mild-to-moderate ulcerative colitis.
Researchers of a new study hope the results will help guide clinicians’ decision making when screening for celiac disease in children and avoid unnecessary invasive follow-up diagnostic testing.
Dr David Schnadower and colleagues in the PECARN probiotic trial assessed the effect of Lactobacillus rhamnosus GG among more than 900 children with acute gastroenteritis.
Researchers of the CALIBER study compared the effectiveness of PPIs with laparoscopic magnetic sphincter augmentation among more than 150 patients with GERD with moderate-to-severe regurgitation.
Infection with HCV has been shown to be associated with an increased risk of cardiovascular disease events, but whether treatment with DAA agents affects this risk is currently unclear.
A new study presented during a late-breaking session at The Liver Meeting evaluated the safety and efficacy of oral seladelpar among more than 100 patients with primary biliary cholangitis.
